Candel Therapeutics (CADL) Stock Price, News & Analysis

Company Overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Key Stats

• Today's Range: $8.03 to $8.61
• 50-Day Range: $6.48 to $12.21
• 52-Week Range: $1.45 to $14.60
• Volume: 551,000 shs
• Average Volume: 2.68 million shs
• Market Capitalization: $266.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Candel Therapeutics Stock Analysis - MarketRank™

Candel Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 399th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Candel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Candel Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Candel Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Candel Therapeutics is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Candel Therapeutics has a P/B Ratio of 18.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

10.29% of the float of Candel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Candel Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Candel Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Candel Therapeutics does not currently pay a dividend.

Dividend Growth

Candel Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.29% of the float of Candel Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Candel Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Candel Therapeutics has recently decreased by 3.19%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.23

News Sentiment

Candel Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Candel Therapeutics this week, compared to 3 articles on an average week.

Search Interest

23 people have searched for CADL on MarketBeat in the last 30 days. This is an increase of 109% compared to the previous 30 days.

MarketBeat Follows

8 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $633,534.00 in company stock.

Percentage Held by Insiders

41.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 13.93% of the stock of Candel Therapeutics is held by institutions.

CADL Stock Analysis - Frequently Asked Questions

How have CADL shares performed this year?

Candel Therapeutics' stock was trading at $8.68 on January 1st, 2025. Since then, CADL stock has decreased by 5.3% and is now trading at $8.22.
View the best growth stocks for 2025 here.

How were Candel Therapeutics' earnings last quarter?

Candel Therapeutics, Inc. (NASDAQ:CADL) released its quarterly earnings data on Thursday, March, 13th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.17.

When did Candel Therapeutics IPO?

Candel Therapeutics (CADL) raised $72 million in an initial public offering on Tuesday, July 27th 2021. The company issued 9,000,000 shares at a price of $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

Who are Candel Therapeutics' major shareholders?

Top institutional shareholders of Candel Therapeutics include Baker BROS. Advisors LP (9.18%), Acorn Capital Advisors LLC (5.97%), Braidwell LP (4.93%) and Portolan Capital Management LLC (2.32%). Insiders that own company stock include Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, William Garrett Nichols, Seshu Tyagarajan, Charles Schoch, Jason Amello and Joseph C Papa.
View institutional ownership trends.

How do I buy shares of Candel Therapeutics?

Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Candel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V).

Company Calendar

• Last Earnings: 3/13/2025
• Today: 3/25/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CADL
• CIK: 1841387
• Web: www.candeltx.com
• Phone: 617-916-5445
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $25.00
• Low Stock Price Target: $15.00
• Potential Upside/Downside: +155.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-37,940,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -629.29%
• Return on Assets: -173.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.18
• Quick Ratio: 1.18

Sales & Book Value

• Annual Sales: $120,000.00
• Price / Sales: 2,224.61
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.44 per share
• Price / Book: 18.68

Miscellaneous

• Outstanding Shares: 32,476,000
• Free Float: 18,966,000
• Market Cap: $266.95 million
• Optionable: Optionable
• Beta: -1.29